Show simple item record

dc.contributor.authorBarriuso, Jorge
dc.contributor.authorMartin, A
dc.contributor.authorChakrabarty, Bipasha
dc.contributor.authorBurghel, G
dc.contributor.authorLamarca, Angela
dc.contributor.authorKamposioras, Konstantinos
dc.contributor.authorMcNamara, Mairead G
dc.contributor.authorClouston, Hamish
dc.contributor.authorHubner, Richard A
dc.contributor.authorO'Dwyer, Sarah T
dc.contributor.authorWallace, A
dc.contributor.authorValle, Juan W
dc.date.accessioned2020-06-15T12:57:34Z
dc.date.available2020-06-15T12:57:34Z
dc.date.issued2020en
dc.identifier.citationBarriuso J, Martin A, Chakrabarty B, Burghel G, Lamarca A, Kamposioras K, et al. Systemic chemotherapy for inoperable goblet cell adenocarcinomas (GCAs) and the role of anti-EGFR antibodies. Neuroendocrinology. 2020;110: 181-.en
dc.identifier.urihttp://hdl.handle.net/10541/622947
dc.language.isoenen
dc.titleSystemic chemotherapy for inoperable goblet cell adenocarcinomas (GCAs) and the role of anti-EGFR antibodiesen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentThe Christie ENETS Centre of Excellence. The Christie NHS Foundation Trust. Division of Cancer Sciences, University of Manchester, Manchesteren
dc.identifier.journalNeuroendocrinologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record